BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on
Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the European Hematology Association, to be held June 10 – 13 in Barcelona.
In a presentation titled Prolonged Leukemia Free Survival Following Blinatumomab Treatment of Patients with Minimal Residual Disease of B Precursor ALL: Updated Results of a Phase 2 Study (abstract # 1700), Professor Ralf Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wurzburg University Hospital, will report updated data from a Phase 2 trial of blinatumomab in patients with MRD-positive acute lymphoblastic leukemia (ALL). Dr. Bargou, the study's principal investigator, will present updated duration of response data on 19 evaluable patients on June 12 from 4:30 – 4:45 PM CET. Earlier results from this trial provided the basis for a pivotal trial that the Company plans to initiate in the third quarter of this year.
In a presentation titled CD3/CD19 bispecific BiTE® Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients: 60 micrograms/square meter/d by Continuous Infusion is Tolerable and Results in Durable Responses, (abstract # 433), Mariele Goebeler, Wurzburg University Hospital, will report updated results from an on-going Phase 1 trial of blinatumomab in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Dr. Goebeler will present an update on the experience of patients treated with blinatumomab utilizing a new dosing algorithm on June 12 from 9:00 – 9:15 AM CET.
At the 2010 American Society of Clinical Oncology Annual Meeting, to be held June 4 – 8 in Chicago, Walter Fiedler, Department of Medicine II, University Hospital Hamburg-Eppendorf will report updated results from an ongoing Phase 1 trial of MT110 in patients with advanced solid tumors. In a poster presentation titled Phase I Safety and Pharmacology Study of the EpCAM/CD3-bispecific BiTE® Antibody MT110 in Patients with Metastatic Colorectal, Gastric or Lung Cancer (abstract # 2573), Dr. Fiedler will present interim findings from this dose escalation study on June 7 from 8:00 AM – 12:00 PM CST.
Abstracts can be found at www.ehaweb.org and www.asco.org.
Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study. The most frequently reported grade 3/4 adverse event was lymphopenia. All other adverse events were infrequent and transient in nature. Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All